Chondrogenic neoplasm

Summary

Chondrogenic neoplasm (MONDO:0024469) is a cancer. A subtype of mesenchymal cell neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	chondrogenic neoplasm
Mondo ID	MONDO:0024469
NCIT	C4755
UMLS	C0476147
MedGen	96904
Is cancer (heuristic)	yes

Also known as: cartilaginous neoplasm · cartilaginous tumor · cartilaginous tumour · chondrogenic neoplasm · chondrogenic tumor · chondrogenic tumour · chondromatous neoplasm · chondromatous tumor · chondromatous tumour · neoplasm of cartilage · neoplasm of the cartilage · tumor of cartilage · tumor of the cartilage · tumour of cartilage · tumour of the cartilage

Disease family

This is a subtype of mesenchymal cell neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › mesenchymal cell neoplasm › chondrogenic neoplasm

Related subtypes (5): pericytic neoplasm, fibroblastic neoplasm, tumor of adipose tissue, myomatous neoplasm, osteogenic neoplasm

Subtypes (1): benign chondrogenic neoplasm

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.